Newsroom | 72787 results

CARROLLTON, Ga.--(BUSINESS WIRE)--Tanner Health and Mercer University School of Medicine celebrated the opening of their Carrollton clinical campus and simulation lab....

シアトル--(BUSINESS WIRE)--（ビジネスワイヤ） -- QIAGEN傘下のスケーラブルかつアクセスしやすいシングルセル・シーケンシング分野のリーダーであるパース・バイオサイエンシズは、同社の認定サービスプロバイダー（CSP）プログラムに、ガーバン医学研究所内のゲノミクス・プラットフォーム・コアファシリティが加入したことを発表しました。今回の提携により、オーストラリア、アジア太平洋地域全般、それ以外の地域においても、高品質でスケーラブルなシングルセル・シーケンシングへのアクセスが拡大することになります。 ガーバンはオーストラリアを代表する医学研究機関の一つであり、ガーバンのゲノミクス・プラットフォームは、細胞の選別、捕捉、そしてシーケンシングにおいて豊富な経験を有しています。認定サービスプロバイダーとして、ガーバンは、この地域の研究者向けにパースの「Evercode WT」キットを提供します。「パースのプロジェクトに対する要望は増え続けており、この技術は実装や運用が容易で、優れたデータを生成できることが分かっています」と、ガーバン研究所の細胞ゲノミクス責任者であるクリス...

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, une société mondiale de recherche sous contrat (CRO) spécialisée dans la découverte et le développement de médicaments oncologiques, a annoncé aujourd’hui avoir rejoint la New Approach Methodologies Developer Coalition (NAMs-DC) du Critical Path Institute (C-Path). Cette initiative collaborative vise à faire progresser la validation, la certification et l’adoption réglementaire de méthodes de recherche innovantes et pertinentes pour l’humain. Crown...

BOSTON--(BUSINESS WIRE)--In a significant move to advance the treatment of patients with inflammatory breast cancer (IBC), Dana-Farber Cancer Institute, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James), and the Inflammatory Breast Cancer Research Foundation today announced a collaborative research initiative uniting two comprehensive IBC clinics. The collaborative research project will include patients from both Dana-Fa...

VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”). Closing of the Financing The Financing consisted of the issuance of 33...

NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics' K8 slowed GA lesion growth 54% and showed a 4.0-letter vision advantage at six months in Phase 2. Phase 3 planned....

DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer’s global drug development expertise with Henry Ford Health’s comprehensive clinical research program and its deep connection to the communities it serves. “Clinical trials are often the first opportunity patients have to access cutting-edge treatments,” said Dr. David Lanfear, Chief Scie...

BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch also introduces newly formulated meal replacements, including the Trilivy Reset Fueling line enhanced with MetaVantage Technology™, a platform of proprietary ingredient formulas intended to optimize metabolism by unlocking key metabolic pathways. The launch of Trilivy marks a major corporate transf...

SOMERSET, N.J.--(BUSINESS WIRE)--ThalassaX Therapeutics United States Ltd announced that the first patient has been successfully dosed in the U.S. Phase I clinical trial of CS231295....

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during th...